GLP-1R Antibody

Product Discontinued

GLP-1R Antibody Summary

• Immunogen: This antibody is specific for the N Terminus Region of the target protein (NM_002062).
• Specificity: This product is specific for Human GLP1R.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: GLP1R
• Purity: Immunogen affinity purified

Applications/Dilutions

• Dilutions:
  • ELISA 1:100-1:2000
  • Western Blot 1:5000-1:20000
• Application Notes: This antibody is useful in ELISA and Western Blot.

Reactivity Notes

Human.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: 20mM Potassium Phosphate (pH 7.0) and 0.15M NaCl
• Preservative: No Preservative
• Purity: Immunogen affinity purified

Notes

Manufactured by SDIX's proprietary Genomic Antibody Technology™. GAT FAQs.

Alternate Names for GLP-1R Antibody

• GLP-1 receptor
• GLP1R
• GLP-1R
• GLP-1-R
• glucagon-like peptide 1 receptor
• MGC138331

Background

GLP1R, a Glucagon Receptor, has been suggested to affect the feelings of satiety or hunger, sensation of glucose levels, control of glucagon sensitivity of islets, and non insulin-dependent diabetes mellitus. Glucagon-like peptide 1 is an incretin hormone produced by enteroendocrine L-cells in the intestinal mucosa. The hormone is released in response to food intake and plays an important role in maintaining blood glucose homeostasis. Stimulation of the GLP-1R by endogenous hormone induces multiple complementary mechanisms, which together result in a lowering of circulating blood glucose levels. These mechanisms include receptor-mediated enhancement of glucose-induced insulin secretion from pancreatic -cells, inhibition of gastric emptying with a delay in the gastrointestinal resorption of nutrients, inhibition of glucagon secretion, and inhibition of food intake. Desensitization of GLP1R on pancreatic beta-cells is one of the causes of non insulin-dependent diabetes mellitus (NIDDM). GLP1R knockout mice are viable, develop normally, but exhibit increased levels of blood glucose following oral glucose challenge in association with diminished levels of circulating insulin. Recently it has been shown that overexpression of glucagon-like peptide-1 receptor improves learning in rats (During et al. 2003). GLP1R has been reported in pancreas, brain, heart, kidney, lung, and stomach. ESTs have been isolated from kidney and skin libraries.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for GLP-1R Antibody (19400002)(4)

Publications using 19400002

• Drucker DJ. The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications Diabetes 2018-09-01 [PMID: 30135132] (WB, Human)
• Baggio LL, Yusta B, Mulvihill EE, Cao X. GLP-1 receptor expression within the human heart. Endocrinology. 2018-02-12 [PMID: 29444223] (WB, Human)
• Garrison C, Lastwika K, Zhang Y et al. Proteomic Analysis, Immune Dysregulation, and Pathway Interconnections With Obesity J Proteome Res. 2017-01-06 [PMID: 27769113] (MiAr)
  
  Details:
  Analysis is performed on plasma proteomic data to identify how obesity can alter pathways and to highlight the risk factor for disease in subjects with a high body mass index.
• Rho JH, Lampe PD. High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays J Proteome Res. 2013-05-03 [PMID: 23541305] (MiAr)
  
  Details:
  A novel method using antibody microarrays is used to detect autoantibody-antigen complexes that can potentially be useful for detection and characterization of diseases.

Bioinformatics

• Gene Symbol: GLP1R
• Entrez:
  • 2740(Human)
• Uniprot:
  • P43220()